Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
- Status
- RECRUITING
- Phase
- NA
Clinical Trials Related to Pancreatic Cancer
Related studies linked through entity extraction aliases.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE2
Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Brodalumab in the Treatment of Immune-Related Adverse Events
- Status
- RECRUITING
- Phase
- PHASE1
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- RECRUITING
- Phase
- PHASE1
Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.
- Status
- RECRUITING
- Phase
- N/A
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
- Status
- SUSPENDED
- Phase
- NA
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
- Status
- RECRUITING
- Phase
- NA
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1
BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro"
- Status
- RECRUITING
- Phase
- NA
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
- Status
- RECRUITING
- Phase
- N/A
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Status
- RECRUITING
- Phase
- NA
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
- Status
- COMPLETED
- Phase
- N/A
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3